**Supplementary table 1.** A snapshot on the prevalence of IPIs among different groups of immunocompromised patients worldwide.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Country, city and year** | **Case** | | | **Ref** |
| **Co-morbidity** | **Overall prevalence (%)** | **Most prevalent parasite** |  |
| Iran, Kashan and Qom  2014-2015 | HIV/AIDS | 25% | *B. hominis* (15.0%), *G.lamblia* (5.0%), *Ent. Hartmanni* (5.0%) | Current study |
| RTR | 12% | *G.lamblia* (6.0%), *C. Mesnili* (4.0%), *Ent.* *coli* (2.0%) |
| HD | 11.9% | *B. hominis* (4.4%), *G.lamblia* (3.0%), *Ent.* *coli* (3.0%), *C. Mesnili* (2.2%), *Ent. Hartmanni* (0.7%), *I. butschilii* (0.7%), |
| Cancer | 6.7% | *B. hominis* (3.3%), *Ent.* *coli* (1.7%), *Ent. histolytica/dispar* (1.7%), *C. Mesnili* (1.7%) |
| Indonesia  (Jakarta)  2008-2009 | Immunocompromised children (HIV, malnutrition, malignancies) | 57% | *B. hominis* (47.6%), *Cryptosporidium* (4.7%) | (1) |
| Egypt (Minia District)  2012 | Chronic diseases, malnutrition, patients under corticosteroid therapy and malignancies | 94% | *Cryptosporidium* spp. (60.2%), *B. hominis* (12.1%), *I. belli* (9.7%), and *Cyclospora caytenensis* (7.8%). | (2) |
| Iran  (Shiraz)  2010-2011 | HIV/AIDS | 9.5% | *Cryptosporidium* spp. (6.4%), *E. bieneusi* (2.2%), *I. belli* (0.6%) | (3) |
| Iran  (Tehran)  2003-2005 | HIV/AIDS | 11.4% | *B. hominis* (6.1%), *G. lamblia* (4.2%), *Cryptosporidium* spp. (0.9%), | (4) |
| Indonesia (Jakarta)  2004-2007 | HIV/AIDS | 84.3% | *B. hominis* (72.4%), *Cryptosporidium* spp. (4.9%), *Cyclospora cayetanensis* (4.5%) and *G. lamblia* (1.9%) | (5) |
| Malaysia  208-2010 | HIV/AIDS | 37.9% | *Ent. histolytica/dispar* (16.8%), *A. lumbricoides* (13.9%), *Cryptosporidium* (12.4%), *I. belli* (10.1%), T*. trichiura* (6.4%), *Cyclospora* spp. (4.9%), *G. lamblia* (3.2%) and hookworm (0.6%) | (6) |
| Australia (Sydney) 2003-2006 | HIV/AIDS | 52.4% | *B. hominis* (18.0%), *Endolimax nana* (10.0%), *G. lamblia* (4.5%), *Ent. coli* (2.9%)*, Cryptosporidium* spp. (2.3%) | (7) |
| Cameroon (Dschang) 2012 | HIV/AIDS | 59.5% | *Ent. coli* (21.42%)*,* *Cryptosporidium* spp. (19.0%), *Ent. histolytica/dispar* (19.0%), *G. lamblia* (2.3%) | (8) |
| China (Fuyang) 2008 | HIV/AIDS | 4.3% | *B. hominis* (16.2%), *Cryptosporidium* spp. (8.3%), Hookworm (3.6%), *G. lamblia* (1.3%) and *Entamoebae* spp. (1.7%) | (9) |
| India (Jamnagar ) 2009-2010 | HIV/AIDS | 50.4% | Cryptosporidium spp. (24.8%), *Ent. histolytica/dispar* (9.0%), *I. belli* (7.7%), Hookworm (6.2%), *Cyclospora* (2.2.%) and Microsporidium (2.2.%) | (10) |
| Ethiopia (Hawassa) 2013-2014 | HIV/AIDS | 35.8% | *Cryptosporidium* (13.2 %), *Ent. histolytica/dispar* (10.2 %), and *G. lamblia* (7.9 %) | (11) |
| Iran  (Bushehr)  2001-2012 | HD | 28.4% | *B. hominis* (9.9%), *Ent. coli* (6.7%), *G.lamblia* (3.4%), *Endolimax nana* (2.3%) | (12) |
| Iran  (Tabriz)  2013-2014 | end‑stage HD | 30.7% | *B. hominis* (14.1 %)and *Cryptosporidium* spp. (11.5 %), *Ent. histolytica/dispar* (2.5%) | (13) |
| India  (New Delhi) 2011-2013 | Transplant recipients | 60.5% | *Cryptosporidium* (21.0%), *G. lamblia* (11.0%), *Hymenolepis nana* (11.0%), *I. belli* (8.0%), *Cyclospora cayetanensis* (5.0%), *B. hominis* (3.0%) and *Strongyloides stercoralis* (3.0%) | (14) |
| Iran  (Isfahan)  2006-2007 | RTR | 33.3% | *Ent. coli* (10.6%), *Endolimax nana* (8.7%), *G. lamblia* (7.4%), *B. hominis* (4.7%) | (15) |
| Iran  (Tehran)  2003-2004 | RTR | 4.5% | *B. hominis* (1.7%), *G. lamblia* (1.4%), *Ent. coli* (0.8%) | (16) |
| Iran  (Mashhad)  2008-2009 | Hematopoitic malignancies | 35.9% | *G.lamblia* (18.0%), *Ent. coli* (6.7%), *B. hominis* (5.6%), *I. butschilii* (2.2%), | (17) |
| Turkey  2001 | leukemia | 76.0% | *B. hominis* (26.0%), *G.lamblia* (14.0%), *Cryptosporidium* (4.0%), *I. butschilii* (4.0%), *Ent. histolytica/dispar* (2.0%) | (18) |

References:

1. Idris NS, Dwipoerwantoro PG, Kurniawan A, Said M. Intestinal parasitic infection of immunocompromised children with diarrhoea: clinical profile and therapeutic response. J Infect Dev Ctries. 2010;4(5):309-17.

2. Abdel-Hafeez EH, Ahmad AK, Ali BA, Moslam FA. Opportunistic parasites among immunosuppressed children in Minia District, Egypt. Korean J Parasitol. 2012;50(1):57-62.

3. Agholi M, Hatam GR, Motazedian MH. HIV/AIDS-associated opportunistic protozoal diarrhea. AIDS research and human retroviruses. 2013;29(1):35-41.

4. Meamar A, Rezaian M, Mohraz M, Zahabian F, Hadighi R, Kia E. A comparative analysis of intestinal parasitic infections between HIV+/AIDS patients and non-HIV infected individuals. Iran J Parasitol. 2007;2(1):1-6.

5. Kurniawan A, Karyadi T, Dwintasari S, Sari I, Yunihastuti E, Djauzi S, et al. Intestinal parasitic infections in HIV/AIDS patients presenting with diarrhoea in Jakarta, Indonesia. Trans R Soc Trop Med Hyg. 2009;103(9):892-8.

6. Asma I, Johari S, Benedict L, Sim L, Lim Y. How common is intestinal parasitidm in HIV-infected patients in Malaysia? Tropical Biomed. 2011;28(2):400-10.

7. Stark D, Fotedar R, Van Hal S, Beebe N, Marriott D, Ellis JT, et al. Prevalence of enteric protozoa in human immunodeficiency virus (HIV)–positive and HIV-negative men who have sex with men from Sydney, Australia. Am J Trop Med Hyg. 2007;76(3):549-52.

8. Nkenfou CN, Nana CT, Payne VK. Intestinal parasitic infections in HIV infected and non-infected patients in a low HIV prevalence region, West-Cameroon. PloS One. 2013;8(2):e57914.

9. Tian L-G, Chen J-X, Wang T-P, Cheng G-J, Steinmann P, Wang F-F, et al. Co-infection of HIV and intestinal parasites in rural area of China. Parasite Vector. 2012;5(1):36.

10. Mathur MK, Verma AK, Makwana GE, Sinha M. Study of opportunistic intestinal parasitic infections in human immunodeficiency virus/acquired immunodeficiency syndrome patients. J Global Infect Dis. 2013;5(4):164.

11. Shimelis T, Tassachew Y, Lambiyo T. Cryptosporidium and other intestinal parasitic infections among HIV patients in southern Ethiopia: significance of improved HIV-related care. Parasite Vector. 2016;9(1):270.

12. Barazesh A, Fouladvand M, Tahmasebi R, Heydari A, Fallahi J. The prevalence of intestinal parasites in hemodialysis patients in Bushehr, Iran. Hemodialysis Int. 2015;19(3):447-51.

13. Omrani VF, Fallahi S, Rostami A, Siyadatpanah A, Barzgarpour G, Mehravar S, et al. Prevalence of intestinal parasite infections and associated clinical symptoms among patients with end-stage renal disease undergoing hemodialysis. Infection. 2015;43(5):537-44.

14. Yadav P, Khalil S, Mirdha BR. Molecular appraisal of intestinal parasitic infection in transplant recipients. Indian J Med Res. 2016;144(2):258-63.

15. Azami M, Sharifi M, Hejazi SH, Tazhibi M. Intestinal parasitic infections in renal transplant recipients. Braz J Infect Dis. 2010;14(1):15-8.

16. Rostami MN, Keshavarz H, Eskandari E, Kia E, Rezaeian M. Intestinal parasitic infections in renal transplant recipients. Iranian J Parasitol. 2007;2(3):16-23.

17. Zabolinejad N, Berenji F, Eshkaftaki EB, Badeii Z, Banihashem A, Afzalaqaei M. Intestinal Parasites in Children with Lymphohematopoietic Malignancy in Iran, Mashhad. Jundishapur J Microbiol. 2013;6(6).

18. Aksoy U, Erbay Ae, Akisu C, Apa Hi, Ozkoc S, Ozturk S. Intestinal parasites in children with neoplasms. Turkish J Pediatr. 2003;45(2):129-32.